Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ENSC | Stock Option | Award | +50K | 50K | Jun 30, 2021 | Common Stock | 50K | $3.21 | Direct | F1 | |||
transaction | ENSC | Stock Option | Award | +65.9K | 65.9K | Jun 30, 2021 | Common Stock | 65.9K | $1.83 | Direct | F1 | |||
transaction | ENSC | Stock Option | Award | +263K | 263K | Jun 30, 2021 | Common Stock | 263K | $1.83 | Direct | F1 | |||
transaction | ENSC | Stock Option | Award | +19.8K | 19.8K | Jun 30, 2021 | Common Stock | 19.8K | $2.59 | Direct | F1 | |||
transaction | ENSC | Stock Option | Award | +988K | 988K | Jun 30, 2021 | Common Stock | 988K | $2.59 | Direct | F1 |
Id | Content |
---|---|
F1 | On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. |